Protara (TARA) grants RSUs and 180,000 options to CSO Zummo

Rhea-AI Filing Summary

Protara Therapeutics reported an equity compensation grant to its Chief Scientific Operations Officer, Jacqueline Zummo. On January 16, 2026, she received 30,000 shares of common stock for $0, issued pursuant to restricted stock unit awards. Following this grant, she beneficially owned 128,861 common shares directly.

The filing also shows a grant of 180,000 stock options with a $5.01 exercise price, recorded at a $0 acquisition cost. The RSUs vest in three equal annual installments on the first, second and third anniversaries of January 16, 2026, contingent on continued service. The options vest 25% on the one-year anniversary of January 16, 2026, with the remaining 75% vesting in 1/48th monthly installments over the next three years, also conditioned on ongoing service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Zummo Jacqueline

Role Chf Scientific Operations Off

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	180,000	$0.00	--
Grant/Award	Common Stock	30,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 180,000 shares (Direct); Common Stock — 128,861 shares (Direct)

Footnotes (1)

1. The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date. 25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zummo Jacqueline

(Last) (First) (Middle)

C/O PROTARA THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 3RD FLOOR

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chf Scientific Operations Off

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/16/2026		A		30,000(1)	A	$0	128,861	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.01	01/16/2026		A		180,000		(2)	01/15/2036	Common Stock	180,000	$0	180,000	D

Explanation of Responses:

1. The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date.

2. 25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

Remarks:

	/s/ Jacqueline Zummo	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Protara Therapeutics (TARA) report for Jacqueline Zummo?

The company reported that Chief Scientific Operations Officer Jacqueline Zummo received 30,000 shares of common stock for $0 and 180,000 stock options on January 16, 2026, as part of her equity compensation.

How many Protara Therapeutics (TARA) shares does Jacqueline Zummo beneficially own after this Form 4?

After the reported grant of restricted stock units, Jacqueline Zummo beneficially owned 128,861 shares of Protara common stock, held directly.

What are the terms of the restricted stock units (RSUs) granted to the Protara (TARA) officer?

The 30,000 RSU-based shares represent rights to receive one share of common stock each and vest in three equal one-third installments on the first, second and third anniversaries of January 16, 2026, subject to her continuous service.

How do the stock options granted to the Protara (TARA) officer vest?

The 180,000 stock options have an exercise price of $5.01 per share. 25% of the options vest on the one-year anniversary of January 16, 2026, and 1/48th of the options vest monthly thereafter over the following three years, conditioned on continued service.

What is the expiration date of the stock options granted by Protara Therapeutics (TARA)?

The 180,000 stock options granted to the officer expire on January 15, 2036, if not exercised earlier in accordance with the plan terms.

Are the reported Protara Therapeutics (TARA) equity awards held directly or indirectly?

Both the 128,861 common shares beneficially owned after the RSU grant and the 180,000 stock options are reported as held under direct ownership.